British biotech execs sour on industry’s 'dire' shape

Investors have sourced on publicly traded biotech companies in a big way. IPOs appear to be a less and less appealing way to cash out venture players. And don't look for any kind of a change near-term.

That bleak message has just been repeated for readers of the Financial Times, who were treated to a series of negative assessments from some of the U.K.'s top biotech execs. Too many trial disappointments in too short a period of time has been fingered for much of the blame. 

One sample of the industry's view: "While there are some very strong companies developing--including Oxford BioMedica, Acambis and Protherics--the sector is really in dire shape," says Glyn Edwards, chief executive of Antisoma.

- read the article in the Financial Times

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.